Abstract
Premature ejaculation is one of the most prevalent sexual disorders affecting men today. The lack of approved therapies has resulted in the prescription of many ‘off-label’ treatments to manage the condition. Selective serotonin reuptake inhibitors have an interesting side effect of prolonging ejaculatory latency. Consequently, these agents are often considered a first line treatment for patients suffering from premature ejaculation. Erectile dysfunction is another common side effect reported by men treated with selective serotonin reuptake inhibitors. Nitric oxide is the primary mediator of erectile function. Preclinical studies have provided evidence that selective serotonin reuptake inhibitors decrease nitric oxide bioavailability. This invited mini-review aims to examine the physiology of the erectile and ejaculatory responses, discuss the indicated and ‘off-label’ clinical utility of selective serotonin reuptake inhibitors, and to summarize evidence from basic science and clinical studies pertaining to mechanisms of how selective serotonin reuptake inhibitor therapy modifies ejaculatory and erectile function.
Keywords: Erectile dysfunction, PE treatment, premature ejaculation, selective serotonin reuptake inhibitor, SSRI.
Current Drug Safety
Title:Selective Serotonin Reuptake Inhibitors for Premature Ejaculation: Review of Erectile and Ejaculatory Side Effects
Volume: 9 Issue: 2
Author(s): George F. Lasker, Fikret Halis and Ahmet Gokce
Affiliation:
Keywords: Erectile dysfunction, PE treatment, premature ejaculation, selective serotonin reuptake inhibitor, SSRI.
Abstract: Premature ejaculation is one of the most prevalent sexual disorders affecting men today. The lack of approved therapies has resulted in the prescription of many ‘off-label’ treatments to manage the condition. Selective serotonin reuptake inhibitors have an interesting side effect of prolonging ejaculatory latency. Consequently, these agents are often considered a first line treatment for patients suffering from premature ejaculation. Erectile dysfunction is another common side effect reported by men treated with selective serotonin reuptake inhibitors. Nitric oxide is the primary mediator of erectile function. Preclinical studies have provided evidence that selective serotonin reuptake inhibitors decrease nitric oxide bioavailability. This invited mini-review aims to examine the physiology of the erectile and ejaculatory responses, discuss the indicated and ‘off-label’ clinical utility of selective serotonin reuptake inhibitors, and to summarize evidence from basic science and clinical studies pertaining to mechanisms of how selective serotonin reuptake inhibitor therapy modifies ejaculatory and erectile function.
Export Options
About this article
Cite this article as:
Lasker F. George, Halis Fikret and Gokce Ahmet, Selective Serotonin Reuptake Inhibitors for Premature Ejaculation: Review of Erectile and Ejaculatory Side Effects, Current Drug Safety 2014; 9 (2) . https://dx.doi.org/10.2174/1574886309666140120095846
DOI https://dx.doi.org/10.2174/1574886309666140120095846 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sodium Selenite as an Anticancer Agent
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Potential of Targeting Protease Activated Receptors in Cardiovascular Diseases
Current Pharmaceutical Design Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets New Therapies to Modulate Post-Infarction Inflammatory Alterations in the Myocardium: State of the Art and Forthcoming Applications
Current Radiopharmaceuticals A Scientific Approach to Anti-Ageing Therapies: State of the Art
Current Pharmaceutical Design Progress of Biological Agents on Psoriatic Arthritis
Current Pharmaceutical Biotechnology Estrogen, Neuroprotection and Neurogenesis after Ischemic Stroke
Current Drug Targets Non Peptidic Urotensin II Antagonists: Perspectives for a New Class of Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry Pomegranate Consumption and Blood Pressure: A Review
Current Pharmaceutical Design Are Calcium Channel Blockers First-Line Drugs for the Treatment of Hypertension and Cardiovascular Disease?
Current Hypertension Reviews Aβ1-40 and Aβ1-42 Plasmatic Levels In Stroke: Influence of Pre-Existing Cognitive Status and Stroke Characteristics#
Current Alzheimer Research The Spatial QRS-T Angle: Implications in Clinical Practice
Current Cardiology Reviews Revision on Renal Sympathetic Ablation in the Treatment of Resistant Hypertension
Current Hypertension Reviews Anti Diabetic Effect of Cherries in Alloxan Induced Diabetic Rats
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Recents Patents for Isolating, Delivering and Tracking Adult Stem Cells in Regenerative Medicine
Recent Patents on Drug Delivery & Formulation An Update on Natural Occurrence and Biological Activity of Chromones
Current Medicinal Chemistry Marine Algae As A Prospective Source For Antidiabetic Compounds – A Brief Review
Current Diabetes Reviews Mycobacterial DNA GyrB Inhibitors: Ligand Based Pharmacophore Modelling and In Vitro Enzyme Inhibition Studies
Current Topics in Medicinal Chemistry Selenium Deficiency in Soils and Crops and its Impact on Animal and Human Health
Current Nutrition & Food Science Anti-Inflammatory Agents in Ageing and Age-Associated Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry